<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Shahid Sadoughi University of Medical Sciences
https://en.ssu.ac.ir/publications/</PublisherName>
				<JournalTitle>Advances in Pharmacology and Therapeutics Journal</JournalTitle>
				<Issn>2783-3445</Issn>
				<Volume>5</Volume>
				<Issue>1</Issue>
				<PubDate PubStatus="epublish">
					<Year>2025</Year>
					<Month>03</Month>
					<Day>16</Day>
				</PubDate>
			</Journal>
<ArticleTitle>In Vitro Antifungal Effects of Duloxetine in Combination with Fluconazole on Fluconazole-Resistant Candida Albicans</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>20</FirstPage>
			<LastPage>30</LastPage>
			<ELocationID EIdType="pii">417</ELocationID>
			
<ELocationID EIdType="doi">10.18502/aptj.v5i1.18132</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Ehsan</FirstName>
					<LastName>Momeni</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Abbas</FirstName>
					<LastName>Alimoradian</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Mojtaba</FirstName>
					<LastName>Didehdar</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Ali</FirstName>
					<LastName>Tajic</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Malihe</FirstName>
					<LastName>Safari</LastName>
<Affiliation></Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>01</Month>
					<Day>18</Day>
				</PubDate>
			</History>
		<Abstract>&lt;strong&gt;Aim:&lt;/strong&gt; This study evaluate the antifungal effects of duloxetine as monotherapy and in combination with fluconazole on fluconazole-resistant &lt;em&gt;C. albicans&lt;/em&gt;.
&lt;strong&gt;Methods:&lt;/strong&gt; In this &lt;em&gt;in vitro&lt;/em&gt; study, a suspension of fluconazole-resistant &lt;em&gt;C. albicans&lt;/em&gt; clinical isolates from oral candidiasis was prepared using the CLSI M37-A3 method. Fluconazole (3 mg/mL) and duloxetine (160 µg/mL) stock solutions were serially diluted 9 times (0.625-160 µg/mL for duloxetine and 0.5-128 µg/mL for fluconazole). Their antifungal activity against &lt;em&gt;C. albicans&lt;/em&gt; were evaluated by the microdilution method through broth media. The minimum inhibitory concentration of duloxetine, fluconazole, and their combination was also determined.
&lt;strong&gt;Results:&lt;/strong&gt; Fluconazole-resistant &lt;em&gt;C. albicans&lt;/em&gt; was only sensitive to 32, 64, and 128 µg/mL fluconazole and 160, 80, and 40 µg/mL duloxetine as monotherapy. It was also sensitive to 80 and 160 µg/mL duloxetine combined with all 9 dilutions of fluconazole, but 40 µg/mL duloxetine was only effective in combination with 16 to 128 µg/mL fluconazole. Fluconazole-resistant &lt;em&gt;C. albicans&lt;/em&gt; was sensitive to 10 and 20 µg/mL duloxetine combined with 32, 64, and 128 µg/mL fluconazole. It was also sensitive to 0.625, 1.25, 2.5, and 5 µg/mL duloxetine combined with 64 and 128 µg/mL fluconazole. The MIC of duloxetine was 40 µg/mL as monotherapy and 16 µg/mL combined with fluconazole.
&lt;strong&gt;Conclusion:&lt;/strong&gt; Duloxetine had antifungal effects and the combination of duloxetine with fluconazole had synergistic effects on inhibited fluconazole -resistant &lt;em&gt;C. albicans&lt;/em&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Candida Albicans</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Fluconazole</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Duloxetine</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://aptjournal.ssu.ac.ir/article_417_d724ee9ab91490fddea150960fcfc4bb.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
